• Media
  • Contact
  • Careers
  • About Us
    • About Us
    • Management
    • Clinical Advisors
  • Science
  • Patients
    • Patients
    • Lung Cancer (NSCLC)
    • Lupus (SLE)
    • Lymphoma
  • Physicians
  • Pipeline
    • Pipeline
    • Abivertinib
    • AC0058
    • AC0002
    • AC0078
  • Media
    • Press Releases
    • Events & Presentations
  • Contact
  • Careers
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients With Moderate to Severe COVID-19  Learn More...

Innovation for Healthier Lives

For Patients
For Physicians

Our Mission

ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients.

Learn about our Product Candidates

Abivertinib
Learn More

AC0058
Learn More

AC0002
Learn More

AC0078
Learn More

  • About Us
    • Clinical Advisors
    • Management
  • Science
  • Patients
    • Lung Cancer (NSCLC)
    • Lupus (SLE)
    • Lymphoma
  • Physicians
  • Pipeline
    • Abivertinib
    • AC0058
    • AC0002
    • AC0078
  • Careers
  • Media
    • Press Releases
    • Events & Presentations
  • Contact
    • Media & Investor Relations
    • Business Development
    • Headquarters
    • Facilities
© 2022 ACEA Therapeutics | All Rights Reserved | Privacy Policy
  • About Us
    • About Us
    • Management
    • Clinical Advisors
  • Science
  • Patients
    • Patients
    • Lung Cancer (NSCLC)
    • Lupus (SLE)
    • Lymphoma
  • Physicians
  • Pipeline
    • Pipeline
    • Abivertinib
    • AC0058
    • AC0002
    • AC0078
  • Media
    • Press Releases
    • Events & Presentations
  • Contact
  • Careers